Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE).


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
03 2019
Historique:
received: 07 09 2018
revised: 15 01 2019
accepted: 15 01 2019
pubmed: 21 1 2019
medline: 14 1 2020
entrez: 21 1 2019
Statut: ppublish

Résumé

To investigate the initial termination rate of status epilepticus (SE) in a large observational study and explore associated variables. Data of adults treated for SE were collected prospectively in centers in Germany, Austria, and Switzerland, during 4.5 years. Incident episodes of 1,049 patients were analyzed using uni- and multivariate statistics to determine factors predicting cessation of SE within 1 hour (for generalized convulsive SE [GCSE]) and 12 hours (for non-GCSE) of initiating treatment. Median age at SE onset was 70 years; most frequent etiologies were remote (32%) and acute (31%). GCSE was documented in 43%. Median latency between SE onset and first treatment was 30 minutes in GCSE and 150 minutes in non-GCSE. The first intravenous compound was a benzodiazepine in 86% in GCSE and 73% in non-GCSE. Bolus doses of the first treatment step were lower than recommended by current guidelines in 76% of GCSE patients and 78% of non-GCSE patients. In 319 GCSE patients (70%), SE was ongoing 1 hour after initiating treatment and in 342 non-GCSE patients (58%) 12 hours after initiating treatment. Multivariate Cox regression demonstrated that use of benzodiazepines as first treatment step and a higher cumulative dose of anticonvulsants within the first period of treatment were associated with shorter time to cessation of SE for both groups. In clinical practice, treatment guidelines were not followed in a substantial proportion of patients. This underdosing correlated with lack of cessation of SE. Our data suggest that sufficiently dosed benzodiazepines should be used as a first treatment step. ANN NEUROL 2019;85:421-432.

Identifiants

pubmed: 30661257
doi: 10.1002/ana.25416
doi:

Substances chimiques

Anticonvulsants 0
Benzodiazepines 12794-10-4
Levetiracetam 44YRR34555

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-432

Informations de copyright

© 2019 American Neurological Association.

Auteurs

Christoph Kellinghaus (C)

Department of Neurology, Klinikum Osnabrück, Osnabrück, Germany.
Epilepsy Center Münster-Osnabrück, Campus Osnabrück, Osnabrück, Germany.

Andrea O Rossetti (AO)

Department of Clinical Neurosciences, CHUV and University of Lausanne, Lausanne, Switzerland.

Eugen Trinka (E)

Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria.
Centre for Cognitive Neuroscience Salzburg, Salzburg, Austria.

Nicolas Lang (N)

Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Theodor W May (TW)

Society for Epilepsy Research, Bielefeld, Germany.

Iris Unterberger (I)

Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

Stephan Rüegg (S)

Department of Neurology, University Hospital Basel, Basel, Switzerland.

Raoul Sutter (R)

Medical Intensive Care Units and Department of Neurology, University Hospital Basel, Basel, Switzerland.

Adam Strzelczyk (A)

Epilepsy Center Hessen-Marburg, Department of Neurology, University Hospitals and Philipps-University Marburg, Marburg, Germany.
Epilepsy Center Frankfurt Rhein-Main, Department of Neurology, University Hospital Frankfurt and Goethe University, Frankfurt, Germany.

Christian Tilz (C)

Department of Neurology, Krankenhaus Barmherzige Brüder, Regensburg, Germany.

Zeljko Uzelac (Z)

Department of Neurology, University Hospital Ulm, Ulm, Germany.

Felix Rosenow (F)

Epilepsy Center Hessen-Marburg, Department of Neurology, University Hospitals and Philipps-University Marburg, Marburg, Germany.
Epilepsy Center Frankfurt Rhein-Main, Department of Neurology, University Hospital Frankfurt and Goethe University, Frankfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH